Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AS1411 Combined With Cytarabine in Relapsed/Refractory AML
NCT00512083Phase 2Completed
- Sponsor
- Antisoma
- Start
- Jul 2007
- Primary completion
- Apr 2009
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 2
01
Overview
A Phase 2 trial of as1411 in acute myeloid leukemia (AML), sponsored by Antisoma. Started Jul 2007; status: completed.
02
Drugs
as1411
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00512083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00512083.